Where to Inject PeptidesA Compound-Level Breakdown

The internet gives you two answers to this question. One camp says "it's all systemic — inject anywhere, doesn't matter." The other says "inject near the injury — always." Both are wrong as blanket statements, and both are missing the actual pharmacology.

Where you inject matters differently depending on the compound. Some peptides trigger signaling cascades that persist for weeks after the molecule clears in minutes — for those, systemic delivery from any injection site can work. Others need to physically bind structural proteins at the injury — for those, local concentration matters because the molecule dilutes rapidly once it enters circulation. And for some, the question isn't about the injection site at all — it's about the route (nasal vs injectable, oral vs subcutaneous) or the reconstitution chemistry that determines whether the injection is tolerable.

This guide covers every major peptide category: where to inject, why, and what the evidence actually supports versus what's practitioner convention without comparative data.

At a Glance

How Peptides Move After Injection

Every peptide in this guide enters systemic circulation within minutes of subcutaneous injection. At the molecular weights involved — 340 Da (GHK-Cu) to 5,000 Da (TB-4) — the molecules diffuse directly into blood capillaries and distribute throughout the body¹. Nothing you inject subcutaneously "stays local."

But that doesn't mean injection site is irrelevant. During those first minutes, the tissue surrounding the injection site is exposed to concentrations orders of magnitude higher than what arrives later via the bloodstream. For peptides that need high local concentration to activate their mechanism, that brief window may be the only time tissue levels reach the threshold. For peptides that work at nanomolar concentrations or trigger self-sustaining cascades, the window doesn't need to be long — systemic delivery is sufficient.

The question isn't "does the peptide stay local?" It doesn't. The question is: does this specific compound need the concentration spike that local injection provides, or does systemic delivery reach its activation threshold? The answer depends on the compound.

Why Injection Site Matters for Some Peptides and Not Others

Peptides work through fundamentally different mechanisms, and those mechanisms have different concentration requirements.

Signaling peptides: flip a switch, the cascade runs itself

GHK-Cu is the clearest example. It triggers gene expression programs — switching on repair cascades (collagen production, inflammatory gene suppression, tissue remodeling) that continue running for days to weeks after the peptide clears in under an hour⁴. The cascade doesn't need the peptide to stay present.

BPC-157 works similarly — it activates repair cascades (blood vessel growth, cell migration, growth hormone receptor expression) that persist long after the peptide clears in under 30 minutes. A single treatment maintained functional improvements for 360 days in a spinal cord model³. But BPC-157 has a complication GHK-Cu doesn't: a concentration threshold problem that changes where you should inject it (see concentration gap below).

Mass-action peptides: need physical presence at threshold

TB-500's active fragment binds individual actin monomers inside cells, one-to-one, building reserve pools for cell migration⁵. This is physical binding, not signaling — you need enough molecules present to bind enough actin to shift the cellular balance. Below threshold, nothing happens.

For TB-500, the brief first-pass concentration window at the injection site may be the difference between reaching binding threshold and not.

The concentration gap

The only formal BPC-157 pharmacokinetic study (He et al. 2022) measured tissue distribution after injection in rats⁶. Skeletal muscle concentration was below plasma at every time point. At typical human doses (250–750 mcg), estimated peak muscle concentration is roughly 0.5–2.6 ng/mL for minutes.

The in vitro studies that demonstrated BPC-157's gene expression effects — growth hormone receptor upregulation, tendon fibroblast migration — required 100–2,000 ng/mL continuously for 24 hours⁷ ⁸.

That's a 50–200x gap between what systemic injection delivers to muscle and what activates the mechanism in a dish.

Local injection near the injury creates a transient concentration in surrounding tissue that's orders of magnitude higher than what arrives via the bloodstream. It's the only injection route where tissue concentrations plausibly approach the effective range, even briefly.

This gap is less severe for GHK-Cu, which works at 1–10 nanomolar (roughly 0.3–3.4 ng/mL)⁴ — well within what systemic delivery can achieve. Which is consistent with Pickart's data showing GHK-Cu works systemically from distant injection⁹.

The honest caveat

No published study has compared subcutaneous injection near an injury versus subcutaneous injection at a distant site for any peptide covered in this guide³ ¹⁰ ¹¹. The "inject near the injury" recommendation is practitioner-derived, supported by pharmacological reasoning and the concentration gap data, but not by a controlled comparison. We're recommending it as the conservative choice — you get both the local concentration advantage and systemic distribution — not as proven superiority.

Where to Inject Semaglutide, Tirzepatide, and Other GLP-1s

Ozempic · Wegovy · Mounjaro · Zepbound · Retatrutide

Abdomen or front of thigh. Upper arm is an option if someone else is injecting.

GLP-1 receptor agonists work on receptors in the brain (appetite regulation), pancreas (insulin secretion), and gut (gastric emptying). These are systemic targets — the peptide needs to reach them via circulation, not concentrate at a specific tissue. Injection site choice affects absorption speed slightly (abdomen is faster than thigh due to higher subcutaneous blood flow²), but not efficacy.

Rotation matters. GLP-1 medications are injected weekly to daily for months or years. Repeated injection at the same site causes lipodystrophy — the fat tissue hardens, thins, or develops lumps, which then alters absorption unpredictably. Rotate between left abdomen, right abdomen, left thigh, right thigh. Move at least 2 cm from the previous injection within each zone.

Pre-filled pens vs reconstituted: Brand-name pens (Ozempic, Mounjaro) come ready to inject. Compounded versions require reconstitution — follow the reconstitution guide and use the dosing calculator to convert concentration to injection volume.

For compound-specific dosing and titration: Semaglutide guide · Tirzepatide guide · Retatrutide guide

Where to Inject BPC-157

Near the injury site when practical. Subcutaneous, 1–2 cm from the injury. For hard-to-reach injuries (spine, deep hip), abdominal injection is the practical alternative.

BPC-157 has the strongest pharmacological case for local injection of any peptide in this guide. The concentration gap between what systemic injection delivers to skeletal muscle (~0.5–2.6 ng/mL for minutes) and what activates its repair cascades in vitro (100–2,000 ng/mL for hours) is 50–200x⁶ ⁷ ⁸. Local injection near the injury is the only route where tissue concentrations plausibly approach the activation threshold, even transiently.

The only human musculoskeletal study used local injection: Lee & Padgett (2021) injected BPC-157 directly into the knee joint of 16 patients. Fourteen of 16 (87.5%) reported significant pain relief, with most lasting over 6 months¹⁰.

Animal studies from the Sikiric lab show positive outcomes from systemic routes too — IP injection heals distant Achilles tendons, MCL tears, and crushed muscle¹² ¹³ ¹⁴. But those studies use intraperitoneal injection (into the abdominal cavity), which may operate through a different pharmacological pathway than subcutaneous injection. IP delivery makes direct contact with peritoneal tissue that has extensive vagal innervation and immune signaling — it may trigger healing through GI-mediated indirect pathways rather than through peptide reaching the distant injury at therapeutic concentration.

Oral BPC-157 (including the PDA formulation) likely works through a different mechanism entirely for musculoskeletal targets — acting locally on gastric tissue where BPC-157 is native, with the GI tract mediating systemic effects through vagal signaling or immune crosstalk. See the BPC-157 guide for oral vs injectable details.

BPC-157 injection by injury location

Shoulder / rotator cuff: SubQ into the deltoid fat pad, 1–2 cm from the point of maximum tenderness. Lateral or posterior approach depending on the specific structure involved.

Knee: SubQ on the medial or lateral side of the knee, depending on which structure is injured. Medial for MCL or medial meniscus. Lateral for LCL. Anterior for patellar tendon.

Back / spine / sciatica: Local injection is impractical for deep spinal structures. Inject abdomen or thigh. The peptide reaches spinal tissue via circulation — the concentration gap applies, but there's no safe way to inject closer.

Elbow (tennis elbow / golfer's elbow): SubQ over the lateral or medial epicondyle, 1–2 cm from the tender point. Thin subcutaneous tissue here — use a short needle and shallow angle.

Achilles / ankle: SubQ into the fat pad adjacent to the Achilles tendon or over the injured ligament. Avoid injecting directly into the tendon itself.

For complete BPC-157 dosing, cycle length, and stacking: BPC-157 guide · Wolverine Stack

Where to Inject TB-500

Near the injury site when practical. Subcutaneous or intramuscular. For hard-to-reach injuries, abdominal or thigh injection is the alternative.

TB-500's mechanism is mass-action: its active fragment (Ac-LKKTE, produced by enzymatic trimming of TB-500 after injection⁵) physically binds actin monomers inside cells. This requires threshold concentration — below it, not enough actin is sequestered to enable cell migration. Above it, repair cells can move and reorganize.

The dilution problem is severe. A 1997 biodistribution study tracked TB-4 after injection in mice: 44.6% of the injected dose was recovered in urine, blood levels crashed within 40 minutes, and meaningful muscle uptake didn't occur until 6 hours — by which point the circulating supply was mostly gone¹⁵.

Multiple research groups independently engineered nanoparticles¹⁶, scaffolds¹⁷, and hydrogels specifically because systemic TB-4 didn't maintain therapeutic tissue concentration. When tested head-to-head, free systemic TB-4 at the same total dose as a locally-targeted nanoparticle formulation produced zero functional improvement in cardiac repair¹⁶. In pigs, systemic IV TB-4 at 6 mg/kg produced no cardioprotective effect on any endpoint¹⁸.

Local injection near the injury provides the highest initial tissue concentration before systemic dilution — the best approximation of the sustained local delivery these engineered systems achieve, though far shorter in duration.

TB-500 vs TB-4: Most products labeled "TB-500" are actually full-length TB-4. Both share the actin-binding domain, but TB-4 also carries anti-fibrotic (Ac-SDKP) and anti-apoptotic active sites that the fragment lacks. Check the Certificate of Analysis: ~800 Da = TB-500 fragment, ~4,900 Da = full TB-4. See the TB-500 guide for the full distinction.

Where to Inject GHK-Cu

Anywhere. Abdomen or thigh for convenience.

GHK-Cu is the exception that proves the rule. Unlike BPC-157 and TB-500, injection site genuinely does not matter much for this peptide — and the reason illustrates why the other compounds benefit from local injection.

GHK-Cu works at nanomolar concentrations (1–10 nM, roughly 0.3–3.4 ng/mL)⁴. This is 30–300x lower than BPC-157's effective threshold. At typical injectable doses (1–3 mg), systemic delivery reaches effective tissue concentrations.

The animal data confirms this directly. Pickart's studies showed that injecting GHK into thigh muscles of rats, mice, and pigs improved healing at distant wound sites — not at the injection site, but at wounds on the back, in implanted wound chambers, and at bone fracture sites⁹. Three species, consistent results. IP injection healed bone fractures⁹.

GHK-Cu's mechanism explains why: it modulates over 4,000 human genes, resetting expression patterns toward repair and remodeling⁴. It's a gene-expression reprogramming signal, not a structural molecule that needs to be physically present at the wound. The signal propagates through the cells it contacts regardless of where it enters circulation.

GHK-Cu's half-life is short (30–60 minutes) due to carboxypeptidase degradation⁴, but the nanomolar effective threshold means even partially degraded systemic doses can reach effective concentrations at distant tissue.

For GHK-Cu dosing and protocol details: GHK-Cu guide

Where to Inject GLOW and KLOW

Abdomen or thigh. Subcutaneous.

GLOW and KLOW are pre-mixed cosmetic blends (GHK-Cu + BPC-157 + TB-4, with KPV added in KLOW). At cosmetic doses, these are systemic protocols — the compounds distribute through circulation to reach skin, hair follicles, and connective tissue throughout the body. Local targeting isn't the goal.

Injection site rotation matters for comfort and to prevent subcutaneous tissue changes from repeated injection. Alternate between left and right abdomen, or abdomen and thigh.

For the difference between cosmetic and injury dosing: GLOW & KLOW Protocol · GLOW/KLOW for Injuries

Where to Inject KPV

Near the injury site if the injury is actively inflamed. Abdomen if inflammation is systemic or gut-targeted.

KPV's injection logic is different from BPC-157 or TB-500 because it doesn't act on the injured tissue directly. Tendons, ligaments, and muscle don't express the PepT1 transporter that KPV uses to enter cells²⁴. Its target is the immune cells — macrophages and T cells — that have migrated to the injury site. Those immune cells do express PepT1, and KPV suppresses their inflammatory signaling (NF-kB) once transported inside²⁴.

Local injection near an inflamed injury puts KPV in high concentration where the immune cell infiltrate is densest. For systemic inflammation or gut conditions (where PepT1 is naturally expressed throughout the intestinal lining), abdominal SubQ or oral KPV is the appropriate route.

For KPV dosing and stacking: KPV guide · Injury Recovery Protocol

Where to Inject Tesamorelin, Sermorelin, and Ipamorelin

Abdomen. Subcutaneous. Deeper injection preferred for tesamorelin.

GH secretagogues act on the pituitary gland to stimulate growth hormone release. The injection site is irrelevant for efficacy — the peptide needs to reach the pituitary via circulation, not concentrate at a specific tissue.

Tesamorelin has a specific injection site problem. Phase III trials showed 30–51% injection site reaction rates (erythema, pruritus, pain)¹⁹. Unlike most peptide injection reactions, these develop progressively over weeks — the tissue sensitizes to repeated tesamorelin exposure through mast cell histamine release. The reactions get worse over time, not better.

Managing tesamorelin injection site reactions:

• Inject deeper. Shallow SubQ puts tesamorelin in close contact with mast cell-rich tissue in the upper dermis. Deeper injection (full needle depth with a ½-inch insulin syringe) reduces mast cell contact.
• Dilute the injection. Larger reconstitution volume spreads the peptide across more tissue, reducing the histamine trigger at any single point.
• Rotate aggressively. Move at least 2–3 cm between injections. Don't return to the same zone for at least a week.
• Use plain BAC water or sterile water per the FDA-approved label. Tesamorelin's 44-amino-acid size makes its mast cell interaction less predictable than the smaller cationic peptides where NaCl ionic shielding helps.

Sermorelin causes mild, transient injection site reactions and facial flushing — generally well-tolerated without special technique.

Ipamorelin has no significant reported injection site issues.

All three are dosed before bed on an empty stomach. For complete protocols: Tesamorelin guide · Sermorelin guide · GH Secretagogue Comparison

Where to Inject Semax and Selank

Intranasal is the preferred route for both. SubQ abdomen works if you prefer injection.

Semax and Selank target the central nervous system — anxiety, cognitive performance, neuroprotection. Intranasal delivery bypasses the blood-brain barrier by traveling along the olfactory nerve directly to the brain, delivering higher CNS concentration per dose than subcutaneous injection. SubQ is systemic — the peptide still reaches the brain via circulation, but less efficiently.

If you're already injecting other peptides daily, SubQ is a reasonable consolidation. If Semax or Selank is the only peptide you're using, intranasal is the better route.

For dosing and protocol details: Semax guide · Selank guide

Where to Inject NAD+

NAD+ is a metabolic coenzyme, not a signaling peptide — it enters the cellular energy pool regardless of injection site. Abdomen or thigh, IM or SubQ, the cells pull it in the same way. A 2019 IV study showed a 2-hour delay before plasma NAD+ levels rose during continuous infusion — cells were absorbing it faster than it could accumulate in blood²⁰.

The challenge with NAD+ isn't where to inject. It's tolerability.

Why NAD+ injections burn

NAD+ in solution is acidic (pH ~3–4) against your body's pH 7.4. That mismatch causes direct chemical irritation — burning that ranges from uncomfortable to significant depending on dose and speed. Reconstituting with standard hypotonic BAC water compounds the problem by adding osmotic cell swelling on top of the acid burn (see injection site reactions below).

Managing NAD+ injection discomfort

• Use buffered NAD+ when available — formulations with sodium bicarbonate or phosphate buffer that neutralize the pH toward physiological levels.
• Reconstitute with isotonic bacteriostatic water (0.9% NaCl) to eliminate the osmotic swelling that compounds the acid burn.
• Inject slowly. Rapid injection concentrates the acidic bolus. Slow injection allows tissue to buffer the pH incrementally.
• IM may be better tolerated than SubQ for larger doses (>100 mg) — deeper tissue has less pain receptor density.
• Split large doses across two injection sites if needed.

SC vs IM vs IV

For complete NAD+ dosing, cycling, and stacking: NAD+ guide · Peptide Calculator

Injection Site Reactions: Why Some Peptides Burn

Not all injection site reactions have the same cause, and not all respond to the same fix. Three mechanisms compound each other — and understanding which one dominates for your peptide determines what to do about it.

1. Osmotic swelling (tonicity mismatch)

Standard bacteriostatic water is hypotonic — roughly 0 mOsm/L versus your body's 290 mOsm/L. When hypotonic fluid is injected subcutaneously, water rushes into cells at the injection site through osmosis. Cells swell, tissue distends, pain receptors fire. You get a welt.

This affects every peptide reconstituted with standard BAC water, but it's a bigger problem at larger injection volumes and when compounded with other irritation sources.

Fix: Reconstitute with isotonic bacteriostatic water (0.9% sodium chloride). This matches your body's osmolarity and eliminates the osmotic gradient.

2. pH mismatch

Some peptides are acidic in solution. NAD+ drops to pH 3–4 when dissolved. Injecting acid into tissue at pH 7.4 causes direct chemical irritation independent of tonicity.

Fix: Use buffered formulations (sodium bicarbonate or phosphate buffer) when available. Isotonic BAC water fixes the tonicity but not the pH — you need both for NAD+.

3. MRGPRX2 mast cell activation (cationic peptides)

This is the mechanism behind the worst injection site reactions — and it's not generic "irritation." MRGPRX2 is a receptor on skin mast cells that recognizes molecules with both positive charge and hydrophobic/aromatic character. When activated, it triggers histamine release, fluid extravasation, and the classic wheal-and-flare.

SS-31 (elamipretide) is a confirmed MRGPRX2 agonist — knockout mice showed ~80% less swelling, and the EC50 (63 µg/mL) is well below clinical injection concentrations²³. MOTS-c carries the same cationic amphiphilic profile (+3 net charge, multiple aromatic residues) and likely activates the same pathway. Sermorelin and ipamorelin also have the charge-and-aromatic signature that triggers MRGPRX2, which explains their reported histamine reactions.

Fix: NaCl helps through a specific mechanism here — ionic shielding. The sodium and chloride ions surround the positive charges on the peptide, dampening the electrostatic interaction with negatively charged residues in the MRGPRX2 binding pocket. Less receptor activation → less mast cell degranulation → less histamine → smaller welt. This is why switching to isotonic BAC water dramatically reduces welts for these compounds — it's not just fixing tonicity, it's actively blocking the receptor interaction.

For SS-31 specifically, a Phase 1 study tested multiple interventions²³: topical mometasone (corticosteroid cream) applied before injection significantly reduced swelling (p=0.0031) without affecting drug absorption. Oral diphenhydramine also helped but caused drowsiness in 50% of subjects. Ice reduced pain but decreased drug absorption by 12–23%.

How they compound

These three mechanisms multiply, not add. Osmotically swollen mast cells are more reactive to MRGPRX2 activation. Acidic pH lowers the activation threshold further. A cationic peptide in hypotonic, acidic solution hits all three at once — producing a reaction far worse than any single factor predicts.

This is why the same peptide can produce massive welts with standard BAC water and tolerable welts with isotonic NaCl BAC water. NaCl addresses two of the three factors simultaneously (tonicity + ionic shielding), leaving only the baseline receptor activation that shielding can't fully block.

When to Use Isotonic Bacteriostatic Water

Isotonic BAC water (with 0.9% NaCl) does two things: it matches your body's osmolarity (fixing tonicity), and for cationic peptides, the sodium and chloride ions provide ionic shielding that dampens MRGPRX2 mast cell activation. Both effects reduce welting, through different mechanisms.

The trade-off: NaCl increases ionic strength in the vial, which can promote peptide aggregation over weeks by reducing electrostatic repulsion between molecules. This is manageable — use reconstituted vials within 1–2 weeks and store refrigerated.

One concern that doesn't hold up: "NaCl reduces efficacy by shielding the peptide's charge." Your interstitial fluid is already ~150 mM NaCl. Once the peptide leaves the injection site and enters circulation, it's in the same ionic environment regardless of what you reconstituted with. The charge shielding from the reconstitution vehicle is a local, transient phenomenon — it affects what happens in the first minutes at the injection site, not what happens hours later at the target tissue. If anything, NaCl may improve absorption of cationic peptides by reducing electrostatic trapping in the negatively charged extracellular matrix at the injection site.

FAQ

Related Topics

• Peptide Reconstitution Guide — Step-by-step reconstitution with BAC water
• Peptide Dosing Calculator — Convert vial concentration to injection volume
• BPC-157 Guide — Complete mechanism, dosing, oral vs injectable
• TB-500 Guide — TB-500 vs TB-4, fragment-specific mechanisms
• Wolverine Stack — BPC-157 + TB-500 protocol for injury recovery
• Injury Recovery Protocol — Full 3-tier framework with 11 compounds
• NAD+ Guide — Dosing, cycling, and the burning question
• GHK-Cu Guide — Copper peptide for tissue remodeling
• GLOW & KLOW Protocol — Cosmetic blend protocols
• Semaglutide Guide — Dosing and titration
• Tirzepatide Guide — Dosing and comparison
• Tesamorelin Guide — GH secretagogue with injection site management
• Peptide Stacking Guide — How compounds combine

References

¹ Subcutaneous absorption by molecular weight — Molecules under ~16 kDa are absorbed primarily by diffusion into blood capillaries. Supersaxo A et al. Pharm Res. 1990;7(2):167-9. PMID 2137911

² Injection site pharmacokinetics (FDA review) — 50% of peptides/small proteins show injection-site-dependent PK, driven by regional blood flow and pre-systemic proteolysis, not local tissue targeting. Zou P et al. J Control Release. 2021;336:425-445. PMID 34186147

³ BPC-157 "biological switch" mechanism — Signaling cascades persist weeks to months; single treatment maintained effects for 360 days in spinal cord model. McGuire FP et al. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMC12446177

⁴ GHK-Cu gene expression and effective concentration — Modulates 4,000+ genes (31% of genome at ≥50% change). Effective at 1–10 nM. Pickart L, Margolina A. Int J Mol Sci. 2018. PMC6073405

⁵ TB-500 prodrug metabolism — Active metabolite is Ac-LKKTE, not TB-500 itself. Serial C-terminal cleavage. Rahaman KA et al. J Chromatogr B. 2024;16(10):1248-1258. PMID 38382158

⁶ BPC-157 pharmacokinetics and tissue distribution — t½ <30 min; skeletal muscle below plasma at all timepoints; kidney highest concentration. He L et al. Front Pharmacol. 2022. PMC9794587

⁷ BPC-157 in vitro effective concentration (GH receptor) — 100–500 ng/mL for 24h to upregulate GH receptor in tendon fibroblasts. Chang CH et al. J Appl Physiol. 2014. PMC6271067

⁸ BPC-157 tendon fibroblast migration threshold — 500–2,000 ng/mL for 24h. Staresinic M et al. J Orthop Res. 2003 / J Appl Physiol. 2011. PMID 21030672

⁹ GHK-Cu systemic healing from distant injection — Thigh injection heals distant wounds in rats, mice, and pigs. IP injection heals bone fractures. Cushman CJ et al. Yale J Biol Med. 2024;97(3):399-413. PMC11426299

¹⁰ BPC-157 human knee study and systematic review — Lee & Padgett: 14/16 pain relief from intraarticular injection. HSS systematic review: 36 studies (35 preclinical, 1 clinical), no route comparison data. Vasireddi N et al. HSS J. 2025. PMC12313605

¹¹ Bauer 2025 literature review — Comprehensive BPC-157 review confirming no local-vs-systemic comparison exists. PMC11859134

¹² BPC-157 IP efficacy for distant MCL — All routes (IP, oral, topical cream) produced comparable healing over 90 days. Cerovecki T et al. J Orthop Res. 2010. PMID 20225319

¹³ BPC-157 IP efficacy for distant muscle crush — Both IP and local cream effective. Novinscak T et al. Surg Today. 2008. PMID 18668315

¹⁴ BPC-157 IP efficacy with corticosteroid impairment — IP and local cream both overcame steroid-impaired healing. Staresinic M et al. Med Sci Monit. 2010. PMID 20190676

¹⁵ TB-4 biodistribution — 44.6% urinary clearance; blood spike at 2 min, crash by 40 min. Mora CA et al. Int J Immunopharmacol. 1997;19(1):1-8. PMID 9226473

¹⁶ Free systemic TB-4 vs targeted delivery — Free IV TB-4 produced zero functional improvement at same dose as fibrin-targeted nanoparticles. Huang G et al. Int J Nanomedicine. 2017;12:3023-3036. PMC5396927

¹⁷ Sustained local TB-4 release via scaffold — Controlled release over 12 days; 93% wound closure in diabetic rats. Ti D et al. Tissue Eng Part A. 2015;21(3-4):541-549. PMID 25204972

¹⁸ Systemic TB-4 failure in pigs — IV 6 mg/kg produced no cardioprotection on any endpoint. Stark C et al. Front Pharmacol. 2016. Frontiers

¹⁹ Tesamorelin injection site reactions — 30–51% reaction rate (erythema, pruritus, pain) vs 21–24% placebo. Progressive mast cell sensitization. Phase III trial data. [Tesamorelin prescribing information]

²⁰ NAD+ tissue uptake kinetics — 2-hour delay before plasma rise during IV infusion, indicating rapid cellular absorption. Grant R et al. Aging Cell. 2019.

²¹ SS-31 injection site reactions — 57% erythema, 47% pruritus, 20% pain in TAZPOWER Phase III trial (40mg daily SubQ for Barth syndrome).

²² Oral BPC-157 for musculoskeletal healing — Per-oral in drinking water produced quadriceps muscle-to-bone reattachment in rats at 90 days. Matek D et al. 2025. PMC11768438

²³ SS-31 MRGPRX2 mast cell activation and mitigation — Elamipretide is a direct MRGPRX2 agonist (EC50 63±13 µg/mL). Phase 1 crossover study (n=10): topical mometasone pre-treatment significantly reduced induration/swelling (p=0.0031) without affecting drug absorption. Ice reduced pain but decreased Cmax by ~23%. Oral diphenhydramine reduced swelling but caused somnolence in 50%. MRGPRX2 knockout mice showed ~80% reduction in tissue extravasation. "Interventions with Potential to Mitigate Injection Site Reactions Following Subcutaneous Elamipretide Administration." Fortune J Health Sci. Fortune Journals

²⁴ KPV PepT1-dependent mechanism — 10 nM KPV suppresses NF-kB in PepT1-expressing cells; zero effect in cells lacking PepT1. PepT1 expressed on intestinal epithelium and immune cells (macrophages, T cells). Not expressed in skeletal muscle or tendon. Dalmasso G et al. Gastroenterology. 2008. PMC2431115

This content is for educational purposes only. Peptides discussed here are investigational compounds. None are FDA-approved for musculoskeletal indications. No human randomized controlled trials exist for multi-peptide combinations. Consult a physician before beginning any peptide protocol.